Tesamorelin 30 mg

Biochem Tesamorelin 30 mg – Growth Hormone-Releasing Hormone Analogue Peptide

Biochem Tesamorelin 30 mg is a formulation labeled as containing tesamorelin, a synthetic peptide analogue of human growth hormone-releasing hormone (GHRH). Tesamorelin belongs to the growth hormone-releasing hormone receptor agonist class and is associated with the physiological regulation of endogenous growth hormone secretion through the hypothalamic-pituitary axis.

Tesamorelin is a modified analogue of human GHRH consisting of 44 amino acid residues. Its structure includes the natural 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoyl modification designed to improve resistance to enzymatic degradation.

Growth hormone-releasing hormone is naturally produced by the hypothalamus and regulates the secretion of growth hormone from somatotroph cells in the anterior pituitary gland. Growth hormone subsequently influences insulin-like growth factor-1 (IGF-1) production and several metabolic pathways involved in protein metabolism, lipid metabolism, and tissue maintenance.

Unlike recombinant human growth hormone (somatropin), which introduces growth hormone directly into the body, tesamorelin stimulates the release of endogenous growth hormone through activation of GHRH receptors.

Tesamorelin is the active ingredient in Egrifta, a branded pharmaceutical product developed for the reduction of excess abdominal visceral adipose tissue in adults with HIV-associated lipodystrophy. Its established clinical effects are specific to studied populations and pharmaceutical formulations.

Clinical studies have demonstrated that pharmaceutical tesamorelin can reduce visceral adipose tissue in adults with HIV-associated lipodystrophy. However, these findings do not establish tesamorelin as a general weight-loss medication or demonstrate equivalent benefits in otherwise healthy individuals.

Tesamorelin influences growth hormone and IGF-1 signaling, but it does not directly activate growth hormone receptors, androgen receptors, or insulin-like growth factor-1 receptors. Its principal pharmacological activity is mediated through GHRH receptor stimulation.

The Biochem Tesamorelin formulation contains a labeled quantity of 30 mg per vial. This represents the total labeled peptide quantity, not an individual administration amount. The precise salt form, excipients, physical presentation, and manufacturing specifications have not been independently verified.

1. Stimulates Endogenous Growth Hormone Secretion

Tesamorelin activates GHRH receptors expressed on somatotroph cells in the anterior pituitary gland. This receptor interaction stimulates endogenous growth hormone release through physiological endocrine signaling pathways.

The resulting growth hormone response depends on functional pituitary tissue and individual endocrine characteristics.

2. Influences the Growth Hormone–IGF-1 Axis

Growth hormone stimulates IGF-1 production, particularly in the liver. Because tesamorelin increases endogenous growth hormone secretion, it can also increase circulating IGF-1 concentrations.

IGF-1 participates in cellular growth, tissue maintenance, and metabolic regulation. Elevated IGF-1 concentrations are also relevant to the monitoring of pharmaceutical tesamorelin treatment.

3. Has Demonstrated Effects on Visceral Adipose Tissue

Clinical trials involving adults with HIV-associated lipodystrophy have demonstrated reductions in abdominal visceral adipose tissue during pharmaceutical tesamorelin treatment.

Visceral adipose tissue is the fat stored around internal abdominal organs. These findings are specific to the studied condition and should not be interpreted as evidence that tesamorelin reliably produces equivalent results in other populations.

4. Influences Lipid Metabolism

Growth hormone participates in the regulation of lipid metabolism and can stimulate lipolysis.

By increasing endogenous growth hormone secretion, tesamorelin may influence lipid utilization and adipose tissue metabolism. The clinical significance of these effects depends on the population and treatment context.

5. Activates Pituitary cAMP Signaling

Tesamorelin binds to GHRH receptors belonging to the G protein-coupled receptor family.

Receptor activation stimulates Gs-associated signaling, adenylyl cyclase activity, and intracellular cyclic adenosine monophosphate production, contributing to growth hormone synthesis and secretion.

6. Influences Metabolic and Endocrine Regulation

Through growth hormone and IGF-1 signaling, tesamorelin can influence several metabolic pathways associated with protein turnover, lipid metabolism, and glucose homeostasis.

Growth hormone may reduce insulin sensitivity, and tesamorelin treatment can increase the risk of glucose intolerance or diabetes in susceptible individuals.

7. Has Been Evaluated in HIV-Associated Lipodystrophy

Tesamorelin has undergone controlled clinical evaluation for the management of excess visceral abdominal fat associated with HIV-related lipodystrophy.

Its clinical effects have included reductions in visceral adipose tissue and changes in selected metabolic measurements. It is not established as a treatment for generalized obesity, age-related growth hormone decline, or athletic performance enhancement.

The biological effects of tesamorelin depend on pituitary responsiveness, systemic exposure, formulation characteristics, and individual metabolic status.

Reported adverse effects include injection-site reactions, joint pain, muscle discomfort, peripheral edema, and hypersensitivity reactions. Clinically important concerns include elevated IGF-1, glucose intolerance, and potential effects on existing malignancies. Tesamorelin is contraindicated in certain conditions involving active malignancy, disrupted hypothalamic-pituitary function, and pregnancy.

Tesamorelin is a modified GHRH analogue that stimulates endogenous growth hormone secretion by activating specific receptors in the anterior pituitary gland.

Its pharmacological effects involve receptor-mediated intracellular signaling followed by growth hormone release and downstream IGF-1-associated metabolic activity.

Step 1 – Introduction Into the Biological System

Tesamorelin enters the biological environment according to its formulation and route of administration.

Established pharmaceutical preparations have been administered by subcutaneous injection, but the administration characteristics of Biochem Tesamorelin 30 mg have not been confirmed.

Step 2 – Interaction With GHRH Receptors

Tesamorelin binds to growth hormone-releasing hormone receptors located on anterior pituitary somatotroph cells.

These receptors belong to the class B family of G protein-coupled receptors and participate in the physiological regulation of growth hormone secretion.

Step 3 – Activation of Intracellular cAMP Signaling

GHRH receptor activation stimulates Gs protein-associated signaling and adenylyl cyclase activity.

This increases intracellular cyclic adenosine monophosphate concentrations and activates signaling processes involved in growth hormone synthesis and secretion.

Step 4 – Stimulation of Growth Hormone and IGF-1 Pathways

Tesamorelin promotes endogenous growth hormone release from responsive pituitary cells.

Growth hormone subsequently interacts with receptors in target tissues and stimulates downstream pathways, including IGF-1 production and metabolic processes associated with lipid and protein regulation.

Step 5 – Peptide Metabolism and Elimination

Tesamorelin undergoes enzymatic peptide degradation and physiological elimination.

Its N-terminal modification improves resistance to certain enzymatic degradation pathways compared with unmodified GHRH, although the peptide remains relatively short-acting.

The elimination half-life of pharmaceutical tesamorelin has been reported at approximately 26–38 minutes following subcutaneous administration, with values varying according to the studied formulation and population.

These pharmacokinetic estimates describe studied pharmaceutical preparations and should not automatically be applied to an independently unverified formulation.

Tesamorelin formulations differ from conventional unmodified GHRH peptides because tesamorelin contains a structural modification intended to improve enzymatic stability while retaining GHRH receptor agonist activity.

Their formulation characteristics may include:

• Tesamorelin as the labeled active ingredient.
• A labeled quantity of 30 mg per vial.
• A synthetic modified peptide containing 44 amino acid residues.
• An N-terminal trans-3-hexenoyl modification.
• Growth hormone-releasing hormone receptor agonist activity.
• Stimulation of endogenous pituitary growth hormone secretion.
• Activation of intracellular cAMP-associated signaling.
• Downstream influence on the growth hormone–IGF-1 axis.
• Lyophilized or liquid presentations, depending on the formulation.
• Excipients selected to support peptide stability.
• Formulation-dependent sensitivity to temperature, moisture, pH, and degradation.
• Packaging and storage requirements determined by the product composition.
• Peptide identity and purity requiring analytical confirmation.

The precise salt form, formulation, excipient composition, and manufacturing specifications of Biochem Tesamorelin 30 mg have not been confirmed.

Formulation ingredients do not independently produce the GHRH receptor agonist activity associated with tesamorelin. The labeled vial strength does not establish an appropriate administration regimen or demonstrate equivalence to a branded pharmaceutical preparation.

United States

Biochem Tesamorelin 30mg, Biochem Tesamorelin 30mg USA, Tesamorelin 30mg United States, Tesamorelin peptide 30mg, Tesamorelin 30mg vial, Tesamorelin GHRH analogue, Tesamorelin Egrifta active ingredient, Tesamorelin properties, Tesamorelin description, Tesamorelin how it works, Tesamorelin composition, Tesamorelin pharmacology, Tesamorelin GHRH receptor, Tesamorelin growth hormone secretion, Tesamorelin IGF-1 pathway, Tesamorelin visceral adipose tissue, Tesamorelin lipid metabolism, Tesamorelin pituitary signaling, Tesamorelin cAMP signaling, Tesamorelin mechanism of action, Tesamorelin peptide structure.

Canada

English: Biochem Tesamorelin 30mg Canada, Tesamorelin peptide 30mg Canada, Tesamorelin 30mg vial, Tesamorelin GHRH analogue, Tesamorelin properties, Tesamorelin formulation, Tesamorelin growth hormone secretion, Tesamorelin IGF-1 signaling, Tesamorelin visceral adipose tissue, Tesamorelin lipid metabolism, Tesamorelin pituitary function, Tesamorelin mechanism of action.

French: Biochem Tésamoréline 30 mg Canada, tésamoréline 30 mg, peptide tésamoréline 30 mg, flacon tésamoréline 30 mg, analogue de la GHRH, propriétés de la tésamoréline, composition de la tésamoréline, sécrétion d'hormone de croissance, récepteur GHRH, axe GH IGF-1, tissu adipeux viscéral, métabolisme lipidique, fonction hypophysaire, mécanisme d'action de la tésamoréline.

United Kingdom

Biochem Tesamorelin 30mg UK, Tesamorelin peptide 30mg UK, Tesamorelin 30mg vial UK, Tesamorelin GHRH analogue, Tesamorelin properties, Tesamorelin pharmacology, Tesamorelin GHRH receptor, Tesamorelin growth hormone secretion, Tesamorelin IGF-1 pathway, Tesamorelin visceral adipose tissue, Tesamorelin lipid metabolism, Tesamorelin pituitary signalling, Tesamorelin peptide composition, Tesamorelin mechanism of action.

Germany

Biochem Tesamorelin 30 mg Deutschland, Tesamorelin 30 mg, Tesamorelin Peptid 30 mg, Tesamorelin 30 mg Fläschchen, GHRH-Analogon, Tesamorelin Eigenschaften, Tesamorelin Wirkungsmechanismus, Tesamorelin Zusammensetzung, Wachstumshormonsekretion, GHRH-Rezeptor, GH-IGF-1-Achse, viszerales Fettgewebe, Fettstoffwechsel, Hypophysenfunktion, cAMP-Signalweg, Tesamorelin Peptidstruktur.

France

Biochem Tésamoréline 30 mg France, tésamoréline 30 mg, peptide tésamoréline 30 mg, flacon tésamoréline 30 mg, analogue de la GHRH, propriétés de la tésamoréline, mécanisme d'action de la tésamoréline, composition de la tésamoréline, sécrétion d'hormone de croissance, récepteur GHRH, axe GH IGF-1, tissu adipeux viscéral, métabolisme lipidique, fonction hypophysaire, signalisation cAMP, structure du peptide tésamoréline.

Spain

Biochem Tesamorelina 30 mg España, tesamorelina 30 mg, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, cómo funciona la tesamorelina, composición de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, señalización cAMP, mecanismo de acción de la tesamorelina.

Italy

Biochem Tesamorelina 30 mg Italia, tesamorelina 30 mg, peptide tesamorelina 30 mg, flaconcino tesamorelina 30 mg, analogo GHRH, proprietà della tesamorelina, meccanismo d'azione tesamorelina, composizione della tesamorelina, secrezione dell'ormone della crescita, recettore GHRH, asse GH IGF-1, tessuto adiposo viscerale, metabolismo lipidico, funzione ipofisaria, segnalazione cAMP, struttura del peptide tesamorelina.

Portugal

Biochem Tesamorelina 30 mg Portugal, tesamorelina 30 mg, peptídeo tesamorelina 30 mg, frasco tesamorelina 30 mg, análogo da GHRH, propriedades da tesamorelina, mecanismo de ação tesamorelina, composição da tesamorelina, secreção da hormona do crescimento, recetor GHRH, eixo GH IGF-1, tecido adiposo visceral, metabolismo lipídico, função hipofisária, sinalização cAMP, estrutura do peptídeo tesamorelina.

Netherlands

Biochem Tesamorelin 30 mg Nederland, tesamoreline 30 mg, tesamoreline peptide 30 mg, tesamoreline 30 mg flacon, GHRH-analoog, eigenschappen van tesamoreline, werkingsmechanisme tesamoreline, samenstelling van tesamoreline, groeihormoonsecretie, GHRH-receptor, GH-IGF-1-as, visceraal vetweefsel, vetmetabolisme, hypofysefunctie, cAMP-signalering, tesamoreline peptidestructuur.

Belgium

Biochem Tesamorelin 30 mg Belgium, Tesamoreline 30 mg België, tésamoréline 30 mg Belgique, tesamoreline peptide, peptide tésamoréline, GHRH-analoog, analogue de la GHRH, eigenschappen van tesamoreline, propriétés de la tésamoréline, groeihormoonsecretie, sécrétion d'hormone de croissance, visceraal vetweefsel, tissu adipeux viscéral, vetmetabolisme, métabolisme lipidique, GH-IGF-1-as.

Switzerland

Biochem Tesamorelin 30 mg Switzerland, Tesamorelin 30 mg Schweiz, tésamoréline 30 mg Suisse, Tesamorelin Peptid, peptide tésamoréline, GHRH-Analogon, analogue de la GHRH, Tesamorelin Eigenschaften, propriétés de la tésamoréline, Wachstumshormonsekretion, sécrétion d'hormone de croissance, viszerales Fettgewebe, tissu adipeux viscéral, Fettstoffwechsel, métabolisme lipidique, GH-IGF-1-Achse.

Austria

Biochem Tesamorelin 30 mg Österreich, Tesamorelin 30 mg, Tesamorelin Peptid 30 mg, Tesamorelin 30 mg Fläschchen, GHRH-Analogon, Tesamorelin Eigenschaften, Tesamorelin Wirkungsmechanismus, Wachstumshormonsekretion, GHRH-Rezeptor, GH-IGF-1-Achse, viszerales Fettgewebe, Fettstoffwechsel, Hypophysenfunktion, cAMP-Signalweg, Tesamorelin Zusammensetzung.

Sweden

Biochem Tesamorelin 30 mg Sverige, tesamorelin 30 mg, tesamorelin peptid 30 mg, tesamorelin 30 mg injektionsflaska, GHRH-analog, tesamorelin egenskaper, tesamorelin verkningsmekanism, tillväxthormonsekretion, GHRH-receptor, GH-IGF-1-axeln, visceralt fett, fettmetabolism, hypofysfunktion, cAMP-signalering, tesamorelin peptidstruktur.

Norway

Biochem Tesamorelin 30 mg Norge, tesamorelin 30 mg, tesamorelin peptid 30 mg, tesamorelin 30 mg hetteglass, GHRH-analog, tesamorelin egenskaper, tesamorelin virkningsmekanisme, veksthormonsekresjon, GHRH-reseptor, GH-IGF-1-aksen, visceralt fett, fettmetabolisme, hypofysefunksjon, cAMP-signalering, tesamorelin peptidstruktur.

Denmark

Biochem Tesamorelin 30 mg Danmark, tesamorelin 30 mg, tesamorelin peptid 30 mg, tesamorelin 30 mg hætteglas, GHRH-analog, tesamorelin egenskaber, tesamorelin virkningsmekanisme, væksthormonsekretion, GHRH-receptor, GH-IGF-1-aksen, visceralt fedt, fedtmetabolisme, hypofysefunktion, cAMP-signalering, tesamorelin peptidstruktur.

Finland

Biochem Tesamorelin 30 mg Suomi, tesamoreliini 30 mg, tesamoreliini peptidi 30 mg, tesamoreliini 30 mg injektiopullo, GHRH-analogi, tesamoreliinin ominaisuudet, tesamoreliinin vaikutusmekanismi, kasvuhormonin eritys, GHRH-reseptori, GH-IGF-1-akseli, viskeraalinen rasvakudos, rasva-aineenvaihdunta, aivolisäkkeen toiminta, cAMP-signalointi, tesamoreliinin peptidirakenne.

Poland

Biochem Tesamorelin 30 mg Polska, tesamorelina 30 mg, peptyd tesamorelina 30 mg, fiolka tesamorelina 30 mg, analog GHRH, właściwości tesamoreliny, mechanizm działania tesamoreliny, skład tesamoreliny, wydzielanie hormonu wzrostu, receptor GHRH, oś GH IGF-1, trzewna tkanka tłuszczowa, metabolizm tłuszczów, funkcja przysadki mózgowej, sygnalizacja cAMP, struktura peptydu tesamorelina.

Czech Republic

Biochem Tesamorelin 30 mg Česko, tesamorelin 30 mg, peptid tesamorelin 30 mg, lahvička tesamorelin 30 mg, analog GHRH, vlastnosti tesamorelinu, mechanismus účinku tesamorelinu, složení tesamorelinu, sekrece růstového hormonu, receptor GHRH, osa GH IGF-1, viscerální tuková tkáň, metabolismus tuků, funkce hypofýzy, signalizace cAMP, struktura peptidu tesamorelin.

Romania

Biochem Tesamorelin 30 mg România, tesamorelină 30 mg, peptidă tesamorelină 30 mg, flacon tesamorelină 30 mg, analog GHRH, proprietăți tesamorelină, mecanism de acțiune tesamorelină, compoziția tesamorelinei, secreția hormonului de creștere, receptor GHRH, axa GH IGF-1, țesut adipos visceral, metabolismul lipidelor, funcția hipofizei, semnalizare cAMP, structura peptidei tesamorelină.

Greece

Biochem Tesamorelin 30 mg Ελλάδα, τεσαμορελίνη 30 mg, πεπτίδιο τεσαμορελίνης 30 mg, φιαλίδιο τεσαμορελίνης 30 mg, ανάλογο GHRH, ιδιότητες τεσαμορελίνης, μηχανισμός δράσης τεσαμορελίνης, σύνθεση τεσαμορελίνης, έκκριση αυξητικής ορμόνης, υποδοχέας GHRH, άξονας GH IGF-1, σπλαχνικός λιπώδης ιστός, μεταβολισμός λιπιδίων, λειτουργία υπόφυσης, σηματοδότηση cAMP, δομή πεπτιδίου τεσαμορελίνης.

Ireland

Biochem Tesamorelin 30mg Ireland, Tesamorelin peptide 30mg Ireland, Tesamorelin 30mg vial Ireland, Tesamorelin GHRH analogue, Tesamorelin properties, Tesamorelin pharmacology, Tesamorelin GHRH receptor, Tesamorelin growth hormone secretion, Tesamorelin IGF-1 pathway, Tesamorelin visceral adipose tissue, Tesamorelin lipid metabolism, Tesamorelin pituitary signalling, Tesamorelin peptide composition, Tesamorelin mechanism of action.

Colombia

Biochem Tesamorelina 30 mg Colombia, tesamorelina 30 mg Colombia, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, cómo funciona la tesamorelina, farmacología de la tesamorelina, composición de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, mecanismo de acción de la tesamorelina, descripción de la tesamorelina.

Argentina

Biochem Tesamorelina 30 mg Argentina, tesamorelina 30 mg Argentina, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, qué es la tesamorelina, cómo actúa la tesamorelina, farmacología de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, composición de la tesamorelina.

México

Biochem Tesamorelina 30 mg México, tesamorelina 30 mg México, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, para qué se utiliza la tesamorelina, cómo funciona la tesamorelina, farmacología de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, mecanismo de acción de la tesamorelina.

Perú

Biochem Tesamorelina 30 mg Perú, tesamorelina 30 mg Perú, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, qué es la tesamorelina, cómo funciona la tesamorelina, farmacología de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, composición de la tesamorelina.

Venezuela

Biochem Tesamorelina 30 mg Venezuela, tesamorelina 30 mg Venezuela, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, qué es la tesamorelina, cómo actúa la tesamorelina, farmacología de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, composición de la tesamorelina.

Ecuador

Biochem Tesamorelina 30 mg Ecuador, tesamorelina 30 mg Ecuador, péptido tesamorelina 30 mg, vial tesamorelina 30 mg, análogo de GHRH, propiedades de la tesamorelina, para qué se utiliza la tesamorelina, cómo funciona la tesamorelina, farmacología de la tesamorelina, secreción de hormona de crecimiento, receptor GHRH, eje GH IGF-1, tejido adiposo visceral, metabolismo de grasas, función hipofisaria, composición de la tesamorelina, mecanismo de acción de la tesamorelina, descripción de la tesamorelina.

Biochem Tesamorelin 30mg | GHRH Analogue Peptide

Learn about Biochem Tesamorelin 30mg, a modified GHRH analogue associated with pituitary growth hormone secretion, IGF-1 signaling, and visceral adipose tissue metabolism.

Biochem Tesamorelina 30mg | Péptido Análogo de GHRH

Conoce Biochem Tesamorelina 30mg, un péptido análogo de GHRH relacionado con la secreción de hormona de crecimiento, la señalización IGF-1 y el metabolismo del tejido adiposo visceral.

biochem-tesamorelin-30mg-ghrh-analogue-peptide

biochem-tesamorelina-30mg-peptido-analogo-ghrh

Biochem Tesamorelin 30mg peptide vial labeled as containing tesamorelin, a modified 44-amino-acid GHRH analogue associated with pituitary growth hormone secretion, IGF-1 signaling, and visceral adipose tissue metabolism.

Biochem Tesamorelina 30mg vial de péptido etiquetado como tesamorelina, un análogo modificado de GHRH de 44 aminoácidos relacionado con la secreción hipofisaria de hormona de crecimiento, la señalización IGF-1 y el metabolismo del tejido adiposo visceral.